Melatonin is a neurohormone known to modulate a wide range of circadian functions, including sleep. The synthesis and release of melatonin from the pineal gland is heavily influenced by light stimulation of the retina, particularly through the intrinsically photosensitive retinal ganglion cells. Melatonin is also synthesised within the eye, although to a much lesser extent than in the pineal gland. Melatonin acts directly on ocular structures to mediate a variety of diurnal rhythms and physiological processes within the eye. The interactions between melatonin, the eye, and visual function have been the subject of a considerable body of recent research. This review is intended to provide a broad introduction for eyecare practitioners and researchers to the topic of melatonin and the eye. The first half of the review describes the anatomy and physiology of melatonin production: how visual inputs affect the pineal production of melatonin; how melatonin is involved in a variety of diurnal rhythms within the eye, including photoreceptor disc shedding, neuronal sensitivity, and intraocular pressure control; and melatonin production and physiological roles in retina, ciliary body, lens and cornea. The second half of the review describes clinical implications of light/melatonin interactions. These include light exposure and photoreceptor contributions in melatonin suppression, leading to consideration of how blue blockers, cataract, and light therapy might affect sleep and mood in patients. Additionally, the interactions between melatonin, sleep and refractive error development are discussed. A better understanding of environmental factors that affect melatonin and subsequent effects on physiological processes will allow clinicians to develop treatments and recommend modifiable behaviours to improve sleep, increase daytime alertness, and regulate ocular and systemic processes related to melatonin.
The visual system feeds into a conscious perception of the world. It can be assessed through functional tests such as acuity, contrast sensitivity, colour vision, and visual field examination. In addition to a role in image formation, the visual system also has a parallel, largely unconscious pathway, through which light exposure influences a large number of physiological processes, such as circadian rhythm, sleep/wake patterns, seasonal timing and reproduction. 1, 2 Melatonin is a major neuromodulatory hormone involved in this pathway. It is produced by the pineal gland, 3 as well as by photoreceptors 4, 5 and the ciliary body epithelium. 6 In both the pineal gland and ocular tissue, melatonin synthesis and release exhibit circadian rhythmicity, with highest levels in darkness, and lowest levels in the light. 7 The pineal gland is the main source of circulating melatonin, which can diffuse into the eye via the ocular vasculature.
Melatonin plays a key role in the coordination of the circadian system, which is the underlying biological clock. 8 In mammals and many other species, circadian rhythms are orchestrated by the suprachiasmatic nucleus. The circadian clock is controlled by molecular oscillators which rely on transcriptional feedback loops. 9 In humans, when external light exposures are removed as a controlling factor, the biological clock has a periodicity slightly greater than 24 hours. 10 The clock is synchronised to exactly 24 hours by the solar day. In the eye, circadian rhythmicity has been well characterised in several processes, including diurnal variations in intraocular pressure, choroidal thickness, and photoreceptor sensitivity and renewal. 11 The relationships between vision, light and melatonin are of increasing relevance for health practitioners and a review on this broad topic may be a useful background for clinicians and researchers. This review discusses ocular and systemic roles of melatonin, its chronobiotic effects, and the influence of environmental light. First, pathways involved in melatonin synthesis and circadian rhythm control are discussed. Then, the impact of artificial lighting and electronic devices on the circadian system and melatonin, and how these factors can be modified through the use of ophthalmic filters in spectacles and intraocular lenses, are reviewed. Finally, clinical aspects of light exposure on sleep and potential relationships with myopia are considered. and melatonin by hydroxyindole-0-methyltransferase (HIOMT) and arylalkylamine N-acetyltransferase (AANAT). 13 AANAT and HIOMT are critical enzymatic mediators of melatonin synthesis, with AANAT being a major rate-limiting step. Circulating melatonin is degraded through several pathways involving multiple enzymatic steps, being primarily metabolised in the liver, kidney, and central nervous system. 14 In humans, melatonin is rapidly metabolised in the liver by hepatic cytochrome P 450 , 15 with a half-life of approximately 45-60 minutes, [16] [17] [18] allowing measures of circulating melatonin in plasma to accurately reflect its synthesis. Melatonin is soluble in lipids and transported in the blood via albumin binding. 19 Three melatonin receptors have been identified -MT1, MT2 and MT3. [20] [21] [22] and MT2 receptors are G protein coupled receptors with seven transmembrane domains. 23 MT1 and MT2 receptors are expressed in the hippocampus, suprachiasmatic nucleus, eye, arteries, heart, gastrointestinal tract, liver, kidneys, adrenal glands, macrophages, and blood platelets. 23, 24 MT1 and MT2 receptor activation leads to modulation of several second messengers, including cyclic adenosine monophosphate (cAMP) and intracellular CA 2+ . The MT3 receptor is considered an enzyme in the reductase group, located in liver, kidney, lung, intestine, muscle, and brown fat tissue. 25 The MT3 receptor is not as well described as MT1 and MT2 receptors, and remains controversial in its characterisation. Melatonin production and release in the pineal gland are mediated by sympathetic innervation and the neurotransmitter norepinephrine. Pineal melatonin is generated by an endogenous oscillator, with photic information from the eye serving to coordinate synthesis and release to the lightdark cycle. 26 Light information is carried from the retina by the intrinsically photosensitive retinal ganglion cells (ipRGCs) through the retinohypothalamic tract to the suprachiasmatic nucleus (Figure 1) . 27, 28 From the suprachiasmatic nucleus, neurons synapse in the paraventricular nucleus of the hypothalamus, then in the upper thoracic intermediolateral cell column. Pre-ganglionic sympathetic fibres synapse in the superior cervical ganglion, and post-ganglionic sympathetic fibres synapse in the pineal gland, whereby the rhythmic production and secretion of melatonin is entrained. Studies have shown that daytime activation of the suprachiasmatic nucleus suppresses melatonin synthesis from the pineal gland via γ-aminobutyric acid (GABA) inhibition at the paraventricular nucleus. 29 ipRGCs express the photopigment melanopsin, and are considered environmental irradiance detectors. 30 Melanopsin is directly activated by light, having a peak sensitivity to short wavelengths at approximately 482 nm. Melanopsin activation contributes to intrinsic ipRGC signalling. 30 Direct photic activation of the ipRGCs through melanopsin mediates non-visual light responses, including circadian rhythm entrainment and pupil size control, 31 and these functions persist even in the absence of rod and cone photoreceptors. Single cell recordings show that ipRGCs exhibit sluggish sustained firing patterns that continue after stimulus offset. 32 In accordance with these response kinetics, ipRGC activity can be assessed in vivo by measuring postillumination pupil responses. 32 Following exposure to short wavelength light of sufficient intensity to activate melanopsin, pupil re-dilation metrics represent a measure of ipRGC activity. 33 ipRGCs also receive extrinsic input through rod and cone pathways. [34] [35] [36] Studies have shown that non-visual light responses, such as melatonin synthesis and circadian phase resetting, can occur through extrinsic rod/cone signalling to the ipRGCs in the absence of melanopsin.
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Ocular melatonin
Ocular sources of melatonin have been studied in a variety of species, and although there may be interspecies differences in sites of melatonin synthesis and receptors, assessing such animal models can provide insight into human melatonin production. In many species, including some amphibians, birds and rodents, melatonin is synthesised locally in the retina under the control of endogenous clocks.
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Other sources of ocular melatonin are believed to be the non-pigmented ciliary epithelium 6 and crystalline lens epithelium. 40 43 and as an antioxidant in the crystalline lens. 44 Melatonin receptors are found throughout the ocular tissue, including the cornea, lens, ciliary body, retina, choroid and sclera ( Figure 2 ). 45 
Retina
Retinal melatonin is synthesised by photoreceptors, and is believed to act locally as a neuromodulator. 46 In humans and rhesus monkey retinae, only trace amounts of HIOMT have been detected; therefore, retinal synthesis may be relatively insignificant in primates. 47 However, circulating melatonin is capable of diffusing into the eye through the ocular vasculature. Melatonin receptors have been localised to the retinal pigment epithelium, photoreceptors, horizontal cells, bipolar cells, amacrine cells, and ganglion cells, as well as the inner and outer plexiform layers. 48, 49 Retinal melatonin has been shown to be metabolised locally within the eye of the African clawed frog, Xenopus laevis, 50 however it is unclear if retinal metabolism of melatonin occurs in mammals.
In the outer retina, melatonin activates outer segment photoreceptor membrane disk shedding. 51 Melatonin has also been implicated in phagocytic activity by the retinal pigment epithelium to take up shed membrane disks, 52 which increases each day after light onset for rods, and after light offset for cones. Additionally, in humans, melatonin protects the retinal pigment epithelium from oxidative stress, which may have protective effects against age-related macular degeneration. 53 MT receptor deficiency has been shown to lead to lipofuscin accumulation and decreased cell viability, as observed in knockout mice. 54 Melatonin also plays a role in phototransduction by altering the sensitivity of photoreceptors and bipolar cells. 55 In the inner retina, melatonin modulates dopamine release. 56, 57 Dopamine mediates light adaptation 58 and circadian changes in visual sensitivity, 59 and entrains circadian rhythms of gene expression in retinal pigment epithelium, photoreceptors, and retinal ganglion cells. [60] [61] [62] [63] [64] [65] Melatonin and dopamine are both under circadian control, and have antagonistic effects in the retina, with melatonin release in darkness, and dopamine release in response to light. Melatonin inhibits dopamine release from amacrine cells, 66 potentially through MT1 receptors, which have been identified on dopaminergic and GABAergic amacrine cells in guinea pigs, humans, and macaques. 49, 67 Light exposure stimulates the release of dopamine from amacrine cells, which binds to D2 and D4 receptors on photoreceptors, inhibiting the activity of AANAT 68 and modulating cAMP and CA +2 levels, thereby decreasing melatonin synthesis. 69 While it has been known that melatonin receptors are found on traditional retinal ganglion cells, 70 researchers have recently localised MT1 and MT2 receptors to ipRGCs. 71 This finding suggests that melatonin may directly influence ipRGC activity. Potential effects of melatonin on ipRGCs include modulating synaptic input from bipolar and amacrine cells or regulating melanopsin synthesis, among others. In any case, melatonin receptor distribution throughout the retina suggests complex interactions between neuronal activity involving melatonin, dopamine and melanopsin.
Ciliary body
Evidence suggests that the ciliary epithelium is another source of ocular melatonin. Support stems from studies which have localised AANAT and HIOMT to the ciliary body of the human eye. 6 Additionally, melatonin has been identified and quantified in aqueous humor, 6, 72, 73 and metabolites of melatonin have been identified in the ciliary processes. 6 In rabbits, melatonin receptors have been found on the iris and ciliary body, and localised to the ciliary epithelium. 74, 75 Melatonin is believed to be involved in aqueous secretion and in maintaining circadian variations in intraocular pressure. Melatonin is greatest at night, when intraocular pressure is generally the lowest; therefore, an inverse relationship exists between melatonin and intraocular pressure. Topical administration of melatonin and its analogues have been shown to decrease intraocular pressure, and thereby modify the circadian pattern. 76 The mechanism of action is thought to be a decrease in chloride efflux and subsequent reduction in aqueous humour formation from the nonpigmented ciliary body epithelial cells, which mediate fluid movement. 77 Links between melatonin, aqueous humour production and intraocular pressure suggest that a role of melatonin in glaucoma pathophysiology and therapy may be plausible (see Rosenstein et al. 78 for review). Glaucoma is a progressive optic neuropathy characterised by loss of retinal ganglion cells and optic nerve changes. Glaucomatous damage to the inner retina has been shown to affect the ipRGCs, 79 which may lead to downstream effects on melatonin and contribute to reported increases in sleep disorders in patients with glaucoma.
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Cornea and ocular surface MT1 receptor expression has been identified in corneal epithelial cells in Xenopus laevis, 79 chicks, and humans. [81] [82] [83] [84] MT2 receptors have been localised to the corneal epithelium, stroma and endothelium in rabbits. 43 The presence of melatonin has been demonstrated in both rabbit and human tears. 43, 85 There is evidence for several potential roles of melatonin on the ocular surface. Melatonin facilitates epithelial desquamation through modulation of tight junction formation and dissociation of surface cells. 84 Melatonin has been shown to affect corneal hydration in vitro. 86 The authors found that melatonin was required note that these findings are from a variety of species including Xenopus laevis, chicks, rabbits, rats and humans 45, 70 for normal corneal growth in vivo in chicks. 86 Melatonin enhances tear secretion in rabbits. 87 With a potential role of melatonin in dermal wound healing 88 and corneal mitotic activity, 89 investigators examined the effects of melatonin on corneal wound healing. 43 In rabbits with epithelial defects, topical melatonin and the MT2 melatonin receptor agonist, IIK7, significantly increased the rate of epithelial migration and wound closure. However, the MT3 melatonin receptor agonist, 5-MCA-NAT, had no effect on wound healing. Therefore, melatonin, acting through MT2 receptors, is likely implicated in corneal wound healing.
Melatonin has also been shown to exhibit antioxidant properties in protection of corneal epithelial cells from ultraviolet (UV) light. 90 Rabbit corneal epithelial cells treated with melatonin had decreased lipid peroxidation and increased mitochondrial viability compared to untreated control tissue following UVB light exposure.
Lens
The role of melatonin in the crystalline lens is at least twofold: (1) controlling transparency through homeostatic processes and (2) reducing oxidative stress. 44 In rats, melatonin, a scavenger of free radicals, has been shown to reduce cataract formation from UVA and UVB exposure. 91 Following UV exposure, exogenously administered melatonin led to decreased lipid peroxidation, increased antioxidant enzyme activity, and decreased CA 2+ , resulting in decreased cataract formation. Melatonin was originally thought to reach the lens through absorption from the aqueous humour. However, recent studies suggest that melatonin may also be synthesised in human lens epithelial cells. Alkozi et al. 40 reported that lens epithelial cells contain melanopsin, with melanopsin activation by light decreasing synthesis of melatonin. Likewise, in darkness, lens epithelial cells increase AANAT expression and melatonin production. Based on the finding that lens epithelial cells contain melanopsin and synthesise melatonin in a light-dependent manner, the authors suggest that it may be possible to modulate melatonin synthesis in the lens by altering illumination conditions, thereby increasing antioxidant properties and decreasing cataract formation. The authors further speculate that modulating melatonin synthesis by the lens at nighttime could be a method to regulate intraocular pressure, which may be beneficial in the treatment of glaucoma. As of yet, this speculation is unproven, but the therapeutic implications warrant further investigation in the area.
In summary, visual processes are major modulators of systemic melatonin production, and melatonin is produced by and has activity in ocular tissues. By altering those visual inputs, it may be possible to influence melatonin production and its systemic and ocular effects in ways that can have clinical and therapeutic implications. The second half of this review will concentrate on some of these potentially modifiable clinical effects.
Light, melatonin and clinical implications
In modern societies, artificial lighting greatly affects biological rhythms. People are increasingly exposed to excess levels of artificial light during the night-time, leading to chronodisruption, and resulting in impaired physiological, behavioural and biochemical rhythms. 92 Even brief exposure to bright light during the night-time can disrupt circadian patterns. Here, the influence of light exposure, the effects of various spectral and temporal properties of light on melatonin, and clinical implications are discussed.
Melatonin and light exposure
Pineal melatonin synthesis and release are directly related to light exposure, and normal circadian rhythms are dependent upon exposure to regular light/dark patterns. Increased night-time melatonin promotes sleep, and decreased daytime melatonin promotes alertness. Light is the most potent Zeitgeber, or time-of-day cue, for regulating circadian activity. Light exposure has been shown to rapidly decrease the activity of AANAT and acutely suppress the production of melatonin. [93] [94] [95] Melatonin undergoes a sharp rise approximately one to three hours before bed-time, which onsets in response to dim light, known as dim light melatonin onset (DLMO, Figure 3) . Similarly, there is a sharp fall in melatonin in response to light onset. DLMO is considered to be a reliable, non-invasive circadian phase marker. Melatonin synthesis from the pineal gland can be estimated through blood, saliva and urine samples. 96 Sample collection over a 24-hour period can provide accurate measures of circadian phase, duration and amplitude.
Blood plasma melatonin levels are approximately three times greater than in saliva; 97 however, plasma sampling can be problematic because collection can be difficult in some subjects, it is invasive, and collection often requires trained medical personnel. Urine samples are analysed for a metabolite of melatonin, 6-sulphatoxymelatonin, which is considered to be a practical method to estimate melatonin production. Saliva sampling is also a practical method to estimate melatonin levels, and collection can be conducted at home.
Photoreceptor contributions to melatonin suppression
The contribution of rod and cone photoreceptors and ipRGCs to melatonin levels can be isolated in experiments using narrowband light of wavelengths specific for each photoreceptor type. Short wavelength light, in the blue portion of the visible spectrum, is most potent for acute suppression of melatonin through activation of melanopsin containing ipRGCs, as discussed earlier.
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Human studies show that red and green light can also suppress melatonin and alter circadian rhythm patterns, 38, 99 despite minimal melanopsin activation, providing evidence that rod and cone photoreceptors contribute to non-visual responses to light. 100 However, the temporal properties of rod and cone photoreceptor and ipRGC sensitivities vary: the effects of rods and cones on non-visual responses are more transient, whereas the effects of ipRGCs are of longer duration. Researchers found that 6.5 hours of either short wavelength (460 nm, activating primarily melanopsin) or medium wavelength (555 nm, activating the three-cone photic system maximally) light during the night initially suppressed melatonin at a similar effective dose. 38 During the second half of the light exposure period, the sensitivity of melatonin suppression to 555 nm light decayed exponentially compared to 460 nm light exposure. The results demonstrated that rod and cone photoreceptors contribute substantially to circadian photoreception, primarily acting in response to short-duration light exposures, while melanopsin expressing ipRGCs respond continuously to long-duration light exposures. Findings also suggested that red light may only suppress melatonin when it is of sufficient intensity.
become ubiquitous in daily life. Of importance, night-time use of electronic devices is highly prevalent, with 90 per cent of Americans reporting electronic device use in the hour before bed-time. 102 Computers, cell phones and video games at night are associated with more difficulties falling asleep and less restful sleep. 102 Increasingly, light bulbs and electronic displays use light emitting diode (LED) light sources, which contain a high proportion of short wavelength light near the peak of ipRGC sensitivity. Accumulating evidence suggests that LED displays are contributing to night-time melatonin suppression and sleep difficulties. 103 Nighttime exposure to back-lit computer displays has been shown to attenuate melatonin. 104 To test the hypothesis that artificial light in the evening suppresses night-time melatonin and decreases sleep quality through an ipRGC-dependent mechanism, a recent study sought to investigate whether reducing short wavelength light exposure at night-time could modulate the ipRGC-driven pupil response, circulating melatonin levels and sleep. 105 Adult subjects wore blueblocking glasses for approximately four hours before bed-time for two weeks.
Results showed that compared to baseline, night-time melatonin significantly increased by 58 per cent (Figure 4 ), objectively measured sleep duration increased an average of 24 minutes, and ipRGC-driven pupil responses increased. Changes in the ipRGC pupil response, as measured in the morning, suggested that a shift in circadian phase occurred, driven by decreased night-time ipRGC input. Researchers concluded that blue-blocking glasses represent a practical method to combat night-time artificial light exposure, phase advance (move earlier) DLMO and improve sleep quality.
Effects of constant darkness on melatonin
As part of a study entitled Project Luma, two adult subjects were sequestered into complete darkness for 10 days. 106 During sequestration, multiple Zeitgebers were provided, and subjects had access to auditoryoutput timepieces. Saliva samples were collected upon waking in the morning, and just before bed at night. Results showed that after 10 days, night-time melatonin decreased from approximately 26 to 16 pg/ml, while morning melatonin increased from 3 to 18 pg/ml, such that by the end of sequestration, night-time and morning melatonin levels were approaching each other ( Figure 5 ). Because only two time-points were assessed, it is unclear whether the diurnal rhythm was abolished completely, or remained in altered pattern; however, the results clearly demonstrate that melatonin release is dependent on light exposure.
Light therapy to modulate melatonin
Light therapy is a non-pharmacological treatment that involves viewing artificial light through a light box or visor to alter circadian rhythms. [107] [108] [109] In mood-related disorders, such as depression, the overall goal of light therapy is to increase the photoperiod, decrease daytime melatonin, and increase night-time melatonin, thereby improving sleep and decreasing depressive symptoms. The mechanism of action of light therapy is through activation of the ipRGCs to ultimately suppress daytime melatonin synthesis and release from the pineal gland. 110 Bright light has been used as a first-line therapy for seasonal depressions (also termed seasonal affective disorder, or SAD) and non-seasonal depression for decades as a means to modulate melatonin and regulate mood 112, 113 (see Goo- months. 112, 114 In depression, circadian rhythm changes typically include effects on sleep 115 and hormone levels. 116 Some studies have shown that patients with seasonal depression have abnormal melatonin levels, including increased daytime melatonin, 117 and phase delays in nighttime melatonin release, 118 although results are not consistent across all studies. 119 Light therapy can also be used to help regulate sleep and mood in jet lag or in shift work-induced sleep disorders. 111 In shift work and in travel that spans over multiple time zones, the timing of the light/dark cycle is altered, leading to temporal misalignments in the circadian system. This chronodisruption can lead to fatigue and poor sleep quality, and has been linked to broad physiological impairments, including increases in gastrointestinal disorders, metabolic syndrome, diabetes, heart disease, and cancer. 120, 121 In such cases, bright light can be used to help reset the circadian system to adapt to irregular light exposure patterns. The timing of the bright light exposure is critical in achieving the desired effects from therapy. For example, nighttime shift workers are advised to undergo light therapy in the evening to suppress melatonin and increase night-time alertness. In jet lag, optimal timing of light therapy depends on the direction of travel, eastward or westward, and number of time zones crossed. 122 For eastward travel, the circadian clock must phase advance, and vice versa for westward travel. Light therapy in combination with melatonin supplements has been shown to be beneficial in resetting circadian time in both shift work and jet lag.
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Cataracts and decreased light transmission
Age-related cataract, or opacification in the crystalline lens, is a leading cause of reversible visual impairment. Cataracts tend to result in a progressive yellowing of the lens and subsequent loss of blue light transmission due to the accumulation of chromophores, which may impact melatonin patterns due to decreased light reaching the ipRGCs. Investigators have sought to understand the impacts of cataracts, cataract surgery, and intraocular lens properties on melatonin levels, sleep quality and daytime alertness. Shenshen et al. evaluated the effects of cataract surgery on salivary melatonin level and sleep quality in ageing patients receiving UV-blocking intraocular lenses. 123 Findings showed that sleep quality improved after cataract surgery, and night-time salivary melatonin increased, with no change in timing of DLMO, suggesting that cataract surgery improved sleep quality via increased bluelight transmission. In support of this theory, another study reported increased photoreception by ipRGCs following cataract removal and intraocular lens implantation. 124 
Blue-blocking spectacles and intraocular lenses
Yellow-tinted lenses, which filter short wavelength blue light, have traditionally been used to improve contrast. More recently, evidence suggests that night-time wear increases melatonin and improves sleep, as discussed above. With increased interest in potential damaging effects of blue light to the retina, the use of blue-blocking lenses, both in spectacles and intraocular lenses, has been increasing. 125 Specifically, studies in animal models and in vitro cell cultures have shown that prolonged exposure to high-intensity light in the short wavelength spectrum can induce phototoxic retinal damage, raising concerns that cumulative exposure to short wavelength light in humans may induce retinal toxicity. 126 Additionally, blue-blocking lenses are widely marketed as a strategy to alleviate computer vision syndrome, also known as digital eye strain, which is a group of vision-related problems resulting from extended electronic device use. These types of blue-blocking technology are promoted for full-time wear in habitual spectacles; however, long-term effects on circadian patterns, melatonin, and in children, eye growth, are unknown.
In an effort to understand potential effects of blue-blocking spectacle lenses on visual performance and sleep-wake cycles, Lawrenson et al. 126 performed a systematic review of the literature. The authors found limited high-quality clinical trials to support the use of blue-blocking lenses. Additionally, the studies evaluated in the review did not address effects of blue-blocking lenses in habitual spectacles on sleep-wake cycles.
While the effects of full-time blue-blocking spectacle lens wear on circadian patterns have not yet been clarified, several studies have investigated the effects of blueblocking intraocular lenses on sleep quality, melatonin and mood. 127, 128 One study found that three weeks after surgery, there were no differences in melatonin and sleep quality between subjects receiving neutral versus blue-blocking intraocular lenses. 124 However, after one year, subjects who received the blue-blocking intraocular lenses demonstrated a 50 per cent lower peak in melatonin compared to subjects who received the neutral intraocular lens. 127 This decrease in melatonin was attributed to a decrease in blue light during the day due to short wavelength absorption from the intraocular lens. Other results between groups regarding sleep and circadian rhythm were variable and inconclusive. In another study, subjects answered a subjective sleep quality questionnaire six months after implantation of a clear, blue-blocking, or UV-blocking intraocular lens. Data showed that implantation of the blue-blocking intraocular lens did not have a negative impact on subjective sleep quality. 128 With variable results and limited information on the effects of habitual blueblocking lens wear on ipRGC function, circadian rhythms and eye growth, further investigations are warranted.
Melatonin, sleep and refractive error
The role of melatonin in refractive error development is not well understood, but the area is receiving more attention with increasing interest in understanding associations between light exposure and refractive error development. The prevalence of myopia, or near-sightedness, has been increasing, with up to 90 per cent prevalence in some eastern Asian populations. 129 While genetics are a major risk factor for the development of myopia, studies show that environmental factors, such as near work and light exposure patterns, also influence eye growth. 130 Accumulating evidence suggests that increased light exposure and time outdoors are protective of myopia. 131, 132 With known roles of dopamine in light adaptation and myopia, 133, 134 and reciprocal interaction between melatonin and dopamine, speculation exists whether melatonin may also play a role in refractive error development. Dopaminergic amacrine cells have also been shown to have reciprocal synapses with ipRGCs, 135 which further implicates melatonin and circadian rhythms in myopia development. In addition to a potential role of melatonin in the pathophysiology of myopia, melatonin may also be altered as a result of structural changes to the inner retina affecting ipRGCs. With myopic eye growth, the retina undergoes stretching and in some cases, retinal degenerations. Disease processes resulting in retinal structural changes, such as glaucoma 79 and age-related macular degeneration, 136 have been shown to reduce ipRGC activity, as assessed through pupil responses, and may lead to subsequent alterations in circadian rhythms, sleep and melatonin synthesis and release. Therefore, it is plausible that myopic retinopathy may also lead to ipRGC damage.
A study in guinea pigs examined the effects of monochromatic light on refractive error and melatonin concentration. 137 Guinea pigs were raised in white light, green light, or blue light. Results showed that guinea pigs raised in green light had significantly higher levels of pineal gland melatonin, whereas guinea pigs raised in blue light had decreased melatonin, presumably as a result of increased ipRGC-induced melatonin suppression. Additionally, guinea pigs raised in green light developed more myopic refractive errors than those raised in blue light. The authors speculated that the increased melatonin experienced by green light potentially induced alterations in retinal growth factors or changes in ocular circadian rhythms that ultimately led to increased eye growth.
A study in chicks showed that systemic administration of melatonin resulted in significant alterations in growth of several ocular tissues in both control animals and those undergoing experimental myopia. 82 Specifically, significant changes were observed in anterior and vitreous chamber depths and choroidal thickness in all animals receiving melatonin. The results suggest that melatonin is involved in the regulation of ocular growth diurnal rhythms, although the exact mechanisms remain elusive. Recent investigations have focused on the role of circadian rhythm on refractive development. Studies in animal models of myopia show that regular intervals of light and dark periods are essential for ocular growth and emmetropisation. For example, constant light 138 and constant dark 139 result in disruptions in eye growth regulation with subsequent refractive errors. In one study, chicks were exposed to two hours of light during the night. 140 This brief period of light exposure disrupted diurnal rhythms in axial length and choroid thickness, and caused an acute, transient stimulation in ocular growth rate. Ultimately, animals exposed to light at night were significantly more myopic than those exposed to continuous darkness at night. The authors suggested that changes in ocular growth were potentially a result of the acute suppression of melatonin by light at night. These findings have implications in how illumination at night might affect ocular growth in children.
A controversial report showed that ambient light at night was associated with myopia development in children. 141 While numerous other studies failed to replicate these findings, [142] [143] [144] the former study raised speculation that light at night and duration of night-time darkness could potentially influence the emmetropisation process in children. In young adult law students, an association was reported between less daily exposure to darkness and myopia progression. 145 Together, these findings warrant further investigations into the influence of light at night and the role of circadian rhythms in refractive development in children.
Kearney et al. 146 148 The odds of myopia were 41 per cent less in subjects with greater than nine hours of sleep per night compared to those with less than five hours of sleep per night. However, another study found that myopic children slept longer than non-myopic children, with both myopia and disordered sleep being prevalent among the subjects. 151 In a recent study, using questionnaire data in adult emmetropes and myopes, sleep quality was reported to be 'poor' for myopic subjects and 'good' for emmetropic subjects. 150 While morning salivary melatonin tended to be higher for the myopic group, differences in melatonin level between refractive error groups did not reach statistical significance. Finally, a recent study in older myopic subjects in east China reported that myopic individuals over 60 years of age slept longer than non-myopic individuals, and that longer sleep duration was associated with decreased sleep quality. 149 However, other factors may have confounded the results on refractive error and sleep in this population, such as the presence of cataract, visual impairments, and other disabilities. Despite several reports of altered sleep quality and melatonin in myopic individuals, the mechanism behind the relationship has yet to be elucidated. Decreased sleep duration and sleep quality in myopic subjects could be attributed to several factors, including stress, academic pressures, workload, and other behavioural and psychological factors. Another potential mechanism for decreased sleep quality may be due to disruptions in circadian rhythms and subsequent decreases in night-time melatonin. Initial reports evaluating ipRGC function and refractive error have not found a direct association between the ipRGC-driven pupil response and myopia. 150, 152 However, another investigation found a significant positive correlation between a more hyperopic refractive error and a slower rate of pupil re-dilation to 0.1 Hz flashing stimuli, which varied as a function of light exposure. 153 Further studies are required to clarify these relationships.
Conclusions
Sleep and mood are interrelated and influenced by environmental factors such as light exposure. Light is the most potent cue for entraining circadian rhythm, primarily through ipRGC pathways to the midbrain. As outlined in this review, melatonin is a key neuromodulator in regulating circadian rhythms, sleep/wake patterns and mood. Additionally, accumulating evidence suggests that melatonin serves numerous other roles in the eye, with implications in corneal wound healing, intraocular pressure regulation, and retinal physiology. With potential roles of light exposure and circadian rhythm in eye growth, speculation exists whether melatonin is implicated in refractive error development; however, further research is required to elucidate relationships. Light exposure, in terms of spectral and temporal properties, represents a modifiable environmental factor, through changes in illumination properties or through use of ophthalmic filters, that may help regulate disorders related to melatonin synthesis and release.
Further studies aimed at identifying the mechanisms of action of ocular and systemic melatonin in humans and understanding the relationships between light exposure, dopamine and melatonin will help to develop targeted environmental and therapeutic interventions that may be beneficial in a variety of ocular and systemic conditions.
